Your browser doesn't support javascript.
loading
Natural compounds-based nanomedicines for cancer treatment: Future directions and challenges.
Andreani, Tatiana; Cheng, Ruoyu; Elbadri, Khalil; Ferro, Claudio; Menezes, Thacilla; Dos Santos, Mayara R; Pereira, Carlos M; Santos, Hélder A.
Afiliación
  • Andreani T; Chemistry Research Centre (CIQUP) and Institute of Molecular Sciences (IMS), Department of Chemistry and Biochemistry, Faculty of Sciences of University of Porto, Rua Do Campo Alegre s/n, 4169-007, Porto, Portugal.
  • Cheng R; GreenUPorto-Sustainable Agrifood Production Research Centre & Inov4Agro, Department of Biology, Faculty of Sciences of University of Porto, Rua Campo Alegre s/n, 4169-007, Porto, Portugal.
  • Elbadri K; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland.
  • Ferro C; Department of Biomaterials and Biomedical Technology, The Personalized Medicine Research Institute Groningen (PRECISION), University Medical Center Groningen, University of Groningen, 9713 AV, Groningen, The Netherlands.
  • Menezes T; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland.
  • Dos Santos MR; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland.
  • Pereira CM; Research Institute for Medicines, iMed.Ulisboa, Faculty of Pharmacy, Universidade de Lisboa, 1649-003, Lisbon, Portugal.
  • Santos HA; Chemistry Research Centre (CIQUP) and Institute of Molecular Sciences (IMS), Department of Chemistry and Biochemistry, Faculty of Sciences of University of Porto, Rua Do Campo Alegre s/n, 4169-007, Porto, Portugal.
Drug Deliv Transl Res ; 14(10): 2845-2916, 2024 Oct.
Article en En | MEDLINE | ID: mdl-39003425
ABSTRACT
Several efforts have been extensively accomplished for the amelioration of the cancer treatments using different types of new drugs and less invasives therapies in comparison with the traditional therapeutic modalities, which are widely associated with numerous drawbacks, such as drug resistance, non-selectivity and high costs, restraining their clinical response. The application of natural compounds for the prevention and treatment of different cancer cells has attracted significant attention from the pharmaceuticals and scientific communities over the past decades. Although the use of nanotechnology in cancer therapy is still in the preliminary stages, the application of nanotherapeutics has demonstrated to decrease the various limitations related to the use of natural compounds, such as physical/chemical instability, poor aqueous solubility, and low bioavailability. Despite the nanotechnology has emerged as a promise to improve the bioavailability of the natural compounds, there are still limited clinical trials performed for their application with various challenges required for the pre-clinical and clinical trials, such as production at an industrial level, assurance of nanotherapeutics long-term stability, physiological barriers and safety and regulatory issues. This review highlights the most recent advances in the nanocarriers for natural compounds secreted from plants, bacteria, fungi, and marine organisms, as well as their role on cell signaling pathways for anticancer treatments. Additionally, the clinical status and the main challenges regarding the natural compounds loaded in nanocarriers for clinical applications were also discussed.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Productos Biológicos / Nanomedicina / Neoplasias / Antineoplásicos Límite: Animals / Humans Idioma: En Revista: Drug Deliv Transl Res Año: 2024 Tipo del documento: Article País de afiliación: Portugal

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Productos Biológicos / Nanomedicina / Neoplasias / Antineoplásicos Límite: Animals / Humans Idioma: En Revista: Drug Deliv Transl Res Año: 2024 Tipo del documento: Article País de afiliación: Portugal